Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

1.

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ.

Cancer Immunol Immunother. 2009 Jan;58(1):49-59. doi: 10.1007/s00262-008-0523-4. Epub 2008 Apr 30.

PMID:
18446337
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.

Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H, Zhao K.

PLoS One. 2013;8(2):e57114. doi: 10.1371/journal.pone.0057114. Epub 2013 Feb 20.

PMID:
23437326
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

[Myeloid-derived suppressor cells in patients with breast cancer].

Gonda K, Shibata M, Ohtake T, Yasuda M, Abe N, Watanabe K, Ando J, Okano M, Onozawa H, Tachibana K, Ohto H, Takenoshita S.

Gan To Kagaku Ryoho. 2012 Sep;39(9):1363-8. Japanese.

PMID:
22996770
[PubMed - indexed for MEDLINE]
4.

Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.

Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, Epstein AL.

J Transl Med. 2011 Jun 9;9:90. doi: 10.1186/1479-5876-9-90.

PMID:
21658270
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.

O'Shaughnessy JA, Denicoff AM, Venzon DJ, Danforth D, Pierce LJ, Frame JN, Bastian A, Ghosh B, Goldspiel B, Miller L, et al.

Ann Oncol. 1994 Oct;5(8):709-16.

PMID:
7826903
[PubMed - indexed for MEDLINE]
6.

High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.

Somlo G, Doroshow JH, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr, Raschko JW, Akman SA, Ahn C, Nagasawa S, et al.

Cancer. 1994 Mar 15;73(6):1678-85.

PMID:
7512436
[PubMed - indexed for MEDLINE]
7.

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.

Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, Michielin O, Romano E, Speiser DE.

Cancer Immunol Immunother. 2014 Mar;63(3):247-57. doi: 10.1007/s00262-013-1508-5. Epub 2013 Dec 20.

PMID:
24357148
[PubMed - indexed for MEDLINE]
8.

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain.

Ann Oncol. 2003 Jun;14(6):833-42. Review.

PMID:
12796019
[PubMed - indexed for MEDLINE]
Free Article
9.

Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.

Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN.

Breast J. 2002 Jan-Feb;8(1):2-9.

PMID:
11856154
[PubMed - indexed for MEDLINE]
10.

High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.

Morgan RJ Jr, Doroshow JH, Venkataraman K, Chang K, Raschko J, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Margolin K, Forman S, Akman S, Coluzzi P, Ahn C, Weiss L, Gadgil U, Harrison J.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2337-45.

PMID:
9815632
[PubMed - indexed for MEDLINE]
Free Article
11.

Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer.

Ohki S, Shibata M, Gonda K, Machida T, Shimura T, Nakamura I, Ohtake T, Koyama Y, Suzuki S, Ohto H, Takenoshita S.

Oncol Rep. 2012 Aug;28(2):453-8. doi: 10.3892/or.2012.1812. Epub 2012 May 14.

PMID:
22614133
[PubMed - indexed for MEDLINE]
12.

Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells.

Hock BD, Mackenzie KA, Cross NB, Taylor KG, Currie MJ, Robinson BA, Simcock JW, McKenzie JL.

Nephrol Dial Transplant. 2012 Jan;27(1):402-10. doi: 10.1093/ndt/gfr264. Epub 2011 May 26.

PMID:
21617199
[PubMed - indexed for MEDLINE]
Free Article
13.

Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.

Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N.

Cancer Res. 2014 Jan 1;74(1):104-18. doi: 10.1158/0008-5472.CAN-13-1545. Epub 2013 Nov 6.

PMID:
24197130
[PubMed - indexed for MEDLINE]
14.

Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.

Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domínguez ME, Rodríguez R, Barbieri MR, Romero Acuña LA, Romero Acuña JM, Langhi MJ, Amato S, Ortiz EH, Vallejo CT, Leone BA.

Cancer J Sci Am. 1998 Mar-Apr;4(2):125-31.

PMID:
9554929
[PubMed - indexed for MEDLINE]
15.

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.

Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF, Korangy F.

Gastroenterology. 2008 Jul;135(1):234-43. doi: 10.1053/j.gastro.2008.03.020. Epub 2008 Mar 21. Erratum in: Gastroenterology. 2011 Aug;141(2):779.

PMID:
18485901
[PubMed - indexed for MEDLINE]
16.

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.

Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH.

Clin Cancer Res. 2009 Mar 15;15(6):2148-57. doi: 10.1158/1078-0432.CCR-08-1332. Epub 2009 Mar 10.

PMID:
19276286
[PubMed - indexed for MEDLINE]
Free Article
17.

IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival.

Kurtenkov O, Klaamas K, Rittenhouse-Olson K, Vahter L, Sergejev B, Miljukhina L, Shljapnikova L.

Exp Oncol. 2005 Jun;27(2):136-40.

PMID:
15995632
[PubMed - indexed for MEDLINE]
18.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
19.

Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer.

Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange JR, Jacobs LK, Emens LA, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, Wolff AC.

J Clin Oncol. 2009 Jun 10;27(17):2816-22. doi: 10.1200/JCO.2008.20.0139. Epub 2009 Mar 30.

PMID:
19332718
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk